VELA Investment Management LLC Buys 6,769 Shares of Zoetis Inc. $ZTS

VELA Investment Management LLC increased its stake in Zoetis Inc. (NYSE:ZTS) by 43.6% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 22,297 shares of the company’s stock after buying an additional 6,769 shares during the quarter. VELA Investment Management LLC’s holdings in Zoetis were worth $1,602,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Prosperity Bancshares Inc bought a new stake in Zoetis in the fourth quarter worth $25,000. Cassaday & Co Wealth Management LLC bought a new position in shares of Zoetis during the first quarter valued at $28,000. Elyxium Wealth LLC purchased a new position in shares of Zoetis in the 4th quarter worth about $32,000. Root Financial Partners LLC raised its position in shares of Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after purchasing an additional 103 shares during the last quarter. Finally, Wellington Grp LLC boosted its stake in Zoetis by 6,675.0% in the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock worth $32,000 after purchasing an additional 267 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 0.1%

Zoetis stock opened at $75.70 on Monday. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. Zoetis Inc. has a one year low of $71.00 and a one year high of $155.15. The stock has a market capitalization of $31.28 billion, a PE ratio of 12.47, a price-to-earnings-growth ratio of 1.77 and a beta of 0.73. The business’s fifty day moving average is $75.53 and its 200 day moving average is $93.61.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.Zoetis’s revenue was down .2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, sell-side analysts predict that Zoetis Inc. will post 6.2 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently commented on the stock. UBS Group cut their price objective on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a research report on Friday, August 7th. Stifel Nicolaus decreased their target price on shares of Zoetis from $85.00 to $80.00 and set a “hold” rating for the company in a report on Thursday, August 20th. BNP Paribas Exane dropped their target price on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 11th. Piper Sandler cut their price target on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a report on Monday, August 10th. Finally, Barclays reduced their price target on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 1st. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Zoetis currently has an average rating of “Hold” and an average price target of $107.43.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.